Edgar Filing: HIXSON HARRY F JR - Form 4

HIXSON H	ARRY F JR								
Form 4									
January 05,	2010								
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								PPROVAL	
Wa Check this box				ashington, D.C. 20549				Number: Expires:	3235-0287 January 31, 2005
Section Form 4	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. Form 4 or					Estimated burden hou	Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type	Responses)								
HIXSON HARRY F JR Sy No			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer			
			NovaBay Pharmaceuticals, Inc. [NBY]				(Check all applicable)		
(Last) C/O NOVA PHARMA	. , , ,	Middle) C, 5980		of Earliest T Day/Year) 2010	ransaction		X Director Officer (giv below)		% Owner her (specify
HORTON	STREET, SUITE	550							
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
EMERYVI	LLE, CA 94608						Form filed by Person	More than One R	eporting
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)				Code Disposed of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		C 1 1	c	Code V		(D) Price	. ,		
Reminder: Re	port on a separate line	e for each cla	ass of sec	unities benef	inclainy ow	ned directly of	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: HIXSON HARRY F JR - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Derivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of D) Instr. 3, 4,		7. Title and A Underlying S (Instr. 3 and	Securitie
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Common Stock (1)	\$ 2.02	01/04/2010		А	36,316	01/04/2010(2)	01/04/2020	Common Stock	36,31

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
HIXSON HARRY F JR C/O NOVABAY PHARMACEUTICALS, INC 5980 HORTON STREET, SUITE 550 EMERYVILLE, CA 94608	Х					
Signatures						
/s/ Theresa Granados, Attorney-in-Fact for Harry Hixson Jr.	/ F.	0	1/05/201	0		
**Signature of Reporting Person			Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Granted persuant to the Novabay Pharmaceuticals, Inc. Director Compnesation Plan.
- (2) Stock Option will vest in equal monthly installments over one year starting from the date of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.